Defiance Amidst Austerity: TAG’s Gala Becomes a Rallying Cry

NEW YORK, NY – July 16, 2026 – In what has become a powerful tradition of resilience, the Treatment Action Group (TAG) announced the first honorees for its 2026 Research in Action Awards (RIAA). The annual gala, a cornerstone for the public health advocacy community, will honor global health advocate Asia Russell and artist Morgan Bassichis. Yet, this year’s celebration on October 15th is cast against the stark backdrop of a systematic dismantling of the very public health infrastructure TAG has fought for decades to build, transforming a night of recognition into a crucial act of financial and political defense.

The Vanguard: Policy and Performance

This year's honorees represent the multifaceted nature of modern activism. Asia Russell, the Executive Director of Health GAP (Global Access Project), embodies the relentless, data-driven fight for policy change. A co-founder of the organization in 1999, Russell has spent over two decades on the front lines, advocating for equitable global access to HIV treatment. Now based in Kampala, Uganda, her work involves building civil society capacity and directly challenging policies that restrict healthcare access, demonstrating a career dedicated to translating high-level advocacy into tangible, life-saving outcomes for communities most affected by the HIV epidemic.

In a complementary role, Morgan Bassichis, an Obie Award-winning writer and performer, exemplifies the power of culture to shape the narrative and sustain a movement. Described by The New Yorker as “fiercely hilarious,” Bassichis uses performance, comedy, and music to explore queer history and radical activism. Their work, including the acclaimed one-person show Can I Be Frank?, serves as a living archive, ensuring that the stories and spirit of queer resistance are not just remembered but are actively engaged with. By honoring both Russell and Bassichis, TAG sends a clear message: the fight to end global epidemics requires both the strategist in the policy room and the artist on the stage.

A System Under Siege

The urgency underpinning the 2026 RIAA cannot be overstated. The event comes at what TAG calls a “pivotal moment,” a diplomatic understatement for an unprecedented assault on public health funding. The Trump Administration has pursued a strategy that threatens to unwind decades of progress. The President’s Emergency Plan for AIDS Relief (PEPFAR), a bipartisan triumph credited with saving millions of lives, has seen its proposed budget slashed from $7.1 billion in 2024 to a mere $2.9 billion for FY 2026. This is not just a budget cut; it is the operationalization of a new “America First Global Health Strategy” that aims to wind down U.S. commitments, with a “stop-work order” already freezing payments and services.

UNAIDS analysis paints a grim picture of the potential consequences, projecting that a permanent discontinuation of PEPFAR could lead to an additional 6.6 million new HIV infections and 4.2 million AIDS-related deaths by 2029. The impact is already being felt, with reports showing approximately two million fewer people on PEPFAR-supported antiretroviral therapy in 2025 compared to the previous year.

The threat is just as severe domestically. The administration’s FY 2026 budget proposes eliminating the CDC's Division of HIV Prevention and making deep cuts to the Ryan White HIV/AIDS Program, a critical lifeline for uninsured and underinsured people living with HIV in the United States. While the Senate has pushed back with a bill to maintain funding, the House has proposed even more drastic measures, setting the stage for a legislative battle with human lives in the balance.

Beyond treatment and prevention programs, the very engine of future progress—scientific research—is being throttled. The National Institutes of Health (NIH) is facing its own cuts and a worrying trend of political interference, with reports of grant funding for HIV, COVID, and Ebola vaccine research being abruptly canceled. TAG has vocally opposed a proposed White House rule that would grant political appointees final authority over federal research grants, a move that would subordinate scientific merit to political alignment.

A Legacy of Resistance

Against this onslaught, TAG’s three-decade history provides a blueprint for resilience. Founded in 1992 by members of ACT UP New York, the organization was born from a refusal to accept the status quo. Its mission, initially focused on accelerating HIV treatment research, has since expanded to include tuberculosis and hepatitis C, recognizing the interconnected nature of these epidemics.

The Research in Action Awards, first held in 1997, have been the financial and spiritual anchor of this mission, raising over $5.5 million to date. The event has consistently brought together a coalition of activists, scientists, artists, and policymakers, honoring luminaries like Dr. Paul Farmer and Dr. Anthony Fauci. It functions as more than a fundraiser; it is a recurring summit for a community dedicated to a shared cause.

“Each year, RIAA gives us the chance to celebrate the people whose courage and work ethic move this fight forward,” said TAG Chief Operating Officer Jason Kirk in the announcement. “Asia Russell and Morgan Bassichis remind us that lasting progress comes from people willing to challenge injustice, build community, and imagine something better.”

These words resonate with particular force in 2026. The funds raised will directly support TAG’s work in dissecting policy, defending research budgets, and ensuring that scientific breakthroughs reach the communities that need them most. As the organization prepares to honor two leaders who embody the spirit of the fight, the RIAA itself stands as a powerful act of defiance, demonstrating that even in the face of political hostility, the community’s commitment to ending these epidemics for everyone, everywhere, remains unbroken.